Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07092527 · ClinicalTrials.gov registry record · Phase 4
Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version
A Phase 4 study of Transgenderism and Reproductive Issues, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT07092527: Recruiting Phase 4 study of Transgenderism and Reproductive Issues, sponsored by University of California, San Diego.
NCT07092527 is a Phase 4 study of Transgenderism and Reproductive Issues that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 80 participants, above the 54-participant average among 5 other Transgenderism trials with a reported enrollment target (48% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07092527, a Phase 4 study of Transgenderism and Reproductive Issues, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study investigates whether male-level exogenous androgens inhibit the reproductive neuroendocrine axis in otherwise healthy (non-PCOS) females.
Primary Outcome
Evidence of Luteal Activity (ELA), as defined by serum progesterone level above 3 ng/mL in transgender men initiating testosterone replacement therapy.
Conditions Studied
Interventions
- DRUG Testosterone Cypionate 50 milligrams per millileter (mg/mL) Injectable Solution
Study Locations (1)
California
- University of California, San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-12-05 |
| Est. Completion | 2028-11-30 |
| Phase | Phase 4 |
What NCT07092527 shows while recruiting
NCT07092527 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 54-participant average among 5 other Transgenderism trials with a reported enrollment target (48% higher).
The record links to 2 conditions, with Transgenderism appearing as the primary indexed condition, and to 1 intervention - of which Testosterone Cypionate 50 milligrams per millileter (mg/mL) Injectable Solution is the first listed.
NCT07092527 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07092527 about?
NCT07092527 is a clinical study titled "Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version". This research study investigates whether male-level exogenous androgens inhibit the reproductive neuroendocrine axis in otherwise healthy (non-PCOS) females.
What is the current status of trial NCT07092527?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2025-12-05. Estimated completion is 2028-11-30.
What conditions does trial NCT07092527 study?
This clinical trial studies the following conditions: Transgenderism, Reproductive Issues.
What interventions are being tested in trial NCT07092527?
The interventions under investigation include: Testosterone Cypionate 50 milligrams per millileter (mg/mL) Injectable Solution (DRUG).
Who is sponsoring clinical trial NCT07092527?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07092527 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transgenderism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Puberty Suppression and Cardiometabolic Health
RECRUITING
-
Pubertal Blockade and Estradiol Effects on Cardiometabolic Health for Transitioning Youth
RECRUITING
-
Cardiometabolic Health in Transgender Males
ACTIVE NOT RECRUITING
-
Transgender Estradiol Affirming Therapy
COMPLETED · Phase 2
-
Effect of Hormone Therapy on Renal Function
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI